ONCAlert | 2017 NANETS Symposium

Latest NewsMORE >>

CMB305, an immunotherapy regimen that generates and expands anti–NY-ESO-1 T cells, demonstrated a favorable survival rate compared with other approved agents for recurrent soft tissue sarcoma, according to results presented at the 2017 ASCO Annual Meeting.

Latest JournalAll Journals >>

Copyright © TargetedOnc 2017 Intellisphere, LLC. All Rights Reserved.